Basic Information
| Drug ID | DDPD00280 |
|
| Drug Name | Disopyramide | |
| Molecular Weight | 339.4745 | |
| Molecular Formula | C21H29N3O | |
| CAS Number | 3737-09-5 | |
| SMILES | CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C | |
| External Links | ||
| DRUGBANK | DB00280 | |
| PubChem Compound | 3114 | |
| PDR | 1182 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.58 | - | 2.58 | - | MANNHOLD,R ET AL. (1993) |
| Melting Point | 94.75 | ℃ | 94.5-95 | ℃ | Cusic, J.W. and Sause, H.W.; U.S. Patent 3,225,054; December 21,1965; assigned to G.D. Searle & Co. |
| Water Solubility | 44.9 | mg/L | 44.9 | mg/L | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Absorption | 100.0 | % | ~100 | % | DRUGBANK | |
| Clearance | 0.0540 | L/h/kg | 0.9 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 0.52 | L/kg | 0.52 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 6.7 | h | 6.7(4-10) | h | DRUGBANK | Half-life | 7.0 | h | 7 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 580.0 | mg/kg | 580.0 | mg/kg | Rattus, Rat; | DRUGBANK |
| Eliminate Route | 50.0 | % | ~50 | % | Urinary excretion; Male, men; normal,healthy; Unchanged drug; | DRUGBANK |
| Protein Binding | 57.5 | % | 50-65 | % | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for infants | 30.0 | mg/kg/day | 30 | mg/kg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
| Max dose for children | 15.0 | mg/kg/day | 15 | mg/kg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
| Max dose for children | 20.0 | mg/kg/day | 20 | mg/kg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
| Max dose for adolescents | 15.0 | mg/kg/day | 15 | mg/kg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
| Max dose for adults | 800.0 | mg/day | 800 | mg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
| Max dose for adults | 1600.0 | mg/day | 1600 | mg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
| Max dose for elderly | 800.0 | mg/day | 800 | mg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
| Max dose for elderly | 1600.0 | mg/day | 1600 | mg/day | PO, oral | Norpace/Norpace CR | disopyramide phosphate | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1